Related Experiment Video
Updated: Feb 15, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
Effect of dimethyl fumarate on gray and white matter pathology in subjects with relapsing multiple sclerosis: a
R Zivadinov1,2, J Hagemeier1, N Bergsland1
1Department of Neurology, Buffalo Neuroimaging Analysis Center, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA.
Background And Purpose:
Dimethyl fumarate (DMF) is an oral treatment for relapsing-remitting multiple sclerosis (MS) with anti-inflammatory and possible neuroprotective properties. Its effect on white matter and gray matter pathology is still not fully understood. The aim of the study was to characterize the effect of DMF on normal-appearing white matter (NAWM) and thalamic pathology longitudinally.
Methods:
In this observational, longitudinal, 24-month magnetic resonance imaging study, 75 patients with relapsing-remitting MS treated with DMF and 40 age- and sex-matched healthy individuals were enrolled. Regional diffusion tensor imaging metrics and tract-based spatial statistics analyses were used to assess differences between groups. Mean diffusivity, axial diffusivity, radial diffusivity and fractional anisotropy were measured in the thalamus and NAWM. Baseline differences and changes over time were evaluated within and between study groups.
Results:
At baseline, patients with MS showed significantly increased diffusivity and decreased fractional anisotropy in the thalamus (P < 0.001 for mean diffusivity, axial diffusivity and radial diffusivity) and NAWM (all P < 0.016) compared with healthy individuals. No significant within-group difference was found in diffusion tensor imaging measures over 24 months in either group. Healthy individuals showed a significantly greater rate of increased diffusivity parameters in the thalamus and NAWM compared with patients with MS, over 24 months (P < 0.05).
Conclusions:
The lack of changes in diffusion tensor imaging metrics in patients with MS over 24 months possibly indicates a neuroprotective role of DMF. These findings provide additional evidence of the beneficial effect of DMF on MS-related pathology.
Insights
Dimethyl fumarate (DMF) may protect against white matter and gray matter damage in multiple sclerosis (MS). This study found DMF-treated MS patients showed less diffusivity changes over 24 months compared to healthy individuals.
Area of Science:
- Neuroscience
- Radiology
- Pharmacology
Background:
- Relapsing-remitting multiple sclerosis (MS) is an inflammatory and neurodegenerative disease.
- Dimethyl fumarate (DMF) is an oral immunomodulator used to treat MS.
- The precise impact of DMF on white matter and gray matter pathology in MS remains incompletely understood.
Purpose of the Study:
- To longitudinally characterize the effects of DMF on normal-appearing white matter (NAWM) and thalamic pathology in patients with MS.
- To compare diffusion tensor imaging (DTI) metrics in the thalamus and NAWM between MS patients treated with DMF and healthy controls over 24 months.
Main Methods:
- An observational, longitudinal 24-month magnetic resonance imaging (MRI) study.
- Inclusion of 75 patients with relapsing-remitting MS treated with DMF and 40 age- and sex-matched healthy controls.
- Assessment of regional DTI metrics (mean diffusivity, axial diffusivity, radial diffusivity, fractional anisotropy) in the thalamus and NAWM using tract-based spatial statistics.
Main Results:
- At baseline, MS patients exhibited significantly higher diffusivity and lower fractional anisotropy in the thalamus and NAWM compared to healthy individuals.
- No significant changes in DTI metrics were observed within either group over the 24-month study period.
- Healthy individuals demonstrated a significantly greater increase in diffusivity parameters in the thalamus and NAWM over 24 months compared to MS patients.
Conclusions:
- The stability of DTI metrics in MS patients treated with DMF over 24 months suggests a potential neuroprotective effect of the drug.
- These findings support the beneficial role of DMF in mitigating MS-related white matter and gray matter pathology.
Related Concept Videos
Longitudinal Studies
Longitudinal Research
Classifying Matter by State
Bioavailability Study Design: Healthy Subjects Versus Patients
The Atomic Theory of Matter
Classifying Matter by Composition
According to its composition, the matter can be classified into two broad categories — pure substances and mixtures.
A pure substance is a form of matter that has a constant composition throughout with uniform properties. For example, any sample of sucrose has the same composition and same physical properties, such as melting point, color, and sweetness, regardless of the source from which it is isolated.
A mixture is composed of two or...

